| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Capstan Therapeutics | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $845M | Series B | 3/20/2024 | $175M | $525.33M | $3.37 | RA Capital Management, Forbion, Johnson & Johnson, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, Vida Ventures | ||||
 | Forward | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.94B | Series E-2 | 8/5/2024 | $146.32M | $928.18M | $5.85 | Undisclosed Investors | ||||
 | nference | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $293.57M | Series C | 12/15/2020 | $62.74M | $858.65M | $7.17 | Matrix Capital Management, Matrix Partners, Mayo Clinic Ventures, NTT Venture Capital | ||||
 | OM1 | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $176.2M | Series D | 7/16/2021 | $85M | $836.02M | $8.90 | D1 Capital Partners, Kaiser Permanente, Breyer Capital, General Catalyst, Polaris Partners, Scale Venture Partners, 7wire Ventures, Glikvest | ||||
 | Paradigm Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $281M | Series B-1 | 12/4/2025 | $57.73M | $505.1M | $1.00 | ARCH Venture Partners, DFJ Growth, F-Prime Capital, General Catalyst, GV, Lux Capital, Mubadala Capital, BrightEdge | ||||
 | Scorpion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.02B | Series C-2 | 7/16/2024 | $24.31M | $821.83M | $2.54 | Frazier Life Sciences, Lightspeed Venture Partners, Willett Advisors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity, Boxer Capital, EcoR1 Capital, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners LP, Casdin Capital | ||||
 | 98point6 | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $267.22M | Series E | 10/15/2020 | $134.21M | $548.43M | $6.59 | L Catterton, Activant Capital, Goldman Sachs | ||||
 | Anumana | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $185.3M | Series C | 4/24/2025 | $95.4M | $568.24M | $5.16 | Boston Scientific Corporation, Matrix Capital, Mayo Clinic, Matrix Partners, NTTVC | ||||
 | Cellarity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $435.63M | Series D | 12/23/2024 | $196.06M | $517.83M | $3.60 | Undisclosed Investors | ||||
 | Click Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $167.96M | Series D-1 | 4/9/2026 | $25M | $567.95M | $6.55 | Boehringer Ingelheim | ||||
 | Rivus Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $224.04M | Series B-2 | 1/16/2025 | $122.98M | $506.82M | $4.76 | RA Capital Management, Bain Capital, BB Biotech AG, Longitutde Capital, Medicxi, RxCapital | ||||
 | Accutar Biotechnology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $207.47M | Series B+4 | 8/20/2021 | $80M | $987.52M | $77.58 | Undisclosed Investors | ||||
 | CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $510.76M | Series F | 8/2/2023 | $105.02M | $615.24M | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | ||||
 | Endeavor BioMedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $295.58M | Series C | 4/24/2024 | $132.58M | $676.04M | $6.52 | AyurMaya, Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, Woodline Partners, Abrdn Inc, Ally Bridge Group, Avidity Partners, Eckuity Capital, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, T. Rowe Price Associates | ||||
 | Lark | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $187.64M | Series D | 10/13/2021 | $100M | $788.69M | $15.42 | Deerfield Management Company, PFM Health Sciences, Franklin Templeton, King River Capital, Castlepeak, IPD, Olive Tree Capital, Weili Dai | ||||
 | Maze Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $503.77M | Series D | 12/3/2024 | $76.4M | $552.39M | $1.38 | Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital | ||||
 | OncoC4 | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $131.23M | Series B | 10/2/2025 | $50M | $619.93M | $4.66 | Greater Bay Area Homeland Investments, HM Capital, 3E Bioventures Capital, Kaitai Capital | ||||
 | Sionna Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.32M | Series C | 3/6/2024 | $181.86M | $523.7M | $9.76 | Enavate Sciences, Viking Global Investors, Perceptive Advisors, RA Capital, TPG, Atlas Venture, Cystic Fibrosis Foundation, T. Rowe Price, Qatar Investment Authority, OrbiMed | ||||
 | Strand Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $266.03M | Series B-2 | 8/7/2025 | $120M | $567.33M | $10.88 | Kinnevik, Regeneron Ventures, ICONIQ Capital, Amgen Ventures, Alderline Group, JIC Venture Growth Investments, LG Technology Ventures, Gradiant, FPV Ventures, Playground Global, Eli Lilly, ANRI, Potentum Partners | ||||
 | Tendo Systems | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $83.48M | Series B | 10/10/2023 | $64.35M | $564.35M | $2.91 | Lux Capital, General Catalyst | ||||
 | Carmot Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $594.61M | Series E | 5/25/2023 | $150M | $696.68M | $23.01 | Deep Track Capital, 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millenium Management, TCGX, Venrock Healthcare Capital Partners, RA Capital Management, The Column Group, Willett Advisors | ||||
 | Enable Injections | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $102.38M | Series B-1 | 1/6/2026 | $30M | $966.49M | $20.02 | Sanofi | ||||
 | Fractyl | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $572.96M | Series F | 6/16/2021 | $100M | $872.9M | $8.38 | Maverick Capital, M28 Capital, Population Health Partners | ||||
 | Orbital Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $373M | Series A | 4/26/2023 | $270M | $705.88M | $1.50 | ARCH Venture Partners, Andreessen Horowitz, Newpath Partners, Abu Dhabi Growth Fund, Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems | ||||